Sorrento Therapeutics Inc (SRNE)

[1776club]

With FUJOVEE having a C-meeting with response from the FDA this month does SCILEX's future hang in the balance? One way or the other the answer is yes. But what about SORRENTO and its future. Mpro looks to be it with P3 data compiled and posted, maybe, this month. Good news in China but how about the US, not so much. In case anyone forgot back in February 2022 there are at least 25 applications from China in drug development phases, planned to be submitted or already under review by the FDA, that are predominantly or solely based on trial data from China, the FDA said ahead of the panel vote, without naming the products. "Single country submission is a step backward in achieving the racial diversity that we need in the United States," Richard Pazdur, director of the FDA's Oncology Center of Excellence, told the panel.
There's trouble in China and that trouble is not only PLAXLOVID
Why Mpro in China you ask?
China’s total Covid-related death count is about 390,000, with a potential range of 77,000 to 945,000 based on fatalities seen in other countries. But that could be very wrong.
BEIJING, Aug 25 (Reuters) - China's abrupt move to dismantle its strict COVID-19 regime, which unleashed the virus onto its 1.4 billion residents, could have led to nearly 2 million excess deaths in the following two months, a new U.S. study shows.

This has doubters but they are educators involved in Equity and look to promote unequitable reasons for higher deaths due to social reasons. "Scientists have identified a gene that doubles the risks of respiratory failure and death from Covid. The latest study homed in on a single gene called LZTFL1, which was revealed to double the risk of respiratory failure and death."
The gene, which changes the way the lungs respond to infection, is the most important genetic risk factor identified so far and is carried by roughly 60% of people with south Asian backgrounds, compared with 15% of those with white European backgrounds. The finding could partly explain the excess deaths seen in some communities in the UK and the impact of Covid-19 in the Indian subcontinent.
Prof James Davies, a geneticist at Oxford University’s Radcliffe Department of Medicine and a senior author of the paper, said: “The genetic factor we have found explains why some people get very seriously ill after coronavirus infection … There’s a single gene that confers quite a significant risk to people of south Asian background.”
From China in January 2023 “State-run nationalist tabloid Global Times on Monday ran an opinion piece blaming “US capital forces” for China’s inability to cut a deal with Pfizer to include the pills in the national insurance. In short, remembering that fellow in NYC, THE PRICE IS TOO DAMN HIGH.
“During the past days, a growing number of US politicians and media outlets have been making shrill ‘warnings’ about the epidemic in China … If they do care about it, why don’t Pfizer drop some pursuit of the profit, and cooperate with China with a little more sincerity?” said the article.
In short, China needs something and that could be Mpro, Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19 waiting top line data from the study in the third quarter of this year (that would be NOW)...but how do we live long enough to prosper. Slowrento needs money to continue, sale of SCILEX stock perhaps or other assets, a partner in China and the US as well as promotion. Still, an RS is still in the cards as well as C7.
Frustration is rising over Covid drug shortages in China, and there are no easy answers